L-165,041 | L-165041 | CAS#79558-09-1 | PPARβ/δ inhibitor

MedKoo Cat#: 406801 | Name: L-165041

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L-165041, also known as L-165,041, is a potent and selective agonist of the nuclear receptor PPARβ/δ (Ki = 9 nM, EC50 = ~500 nM for hPPARβ/δ). L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism. L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ. L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle.

Chemical Structure

L-165041

CAS#79558-09-1

Theoretical Analysis

MedKoo Cat#: 406801

Name: L-165041

CAS#: 79558-09-1

Chemical Formula: C22H26O7

Exact Mass: 402.1679

Molecular Weight: 402.44

Elemental Analysis: Elemental Analysis: C, 65.66; H, 6.51; O, 27.83

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 315.00	2 Weeks
25mg	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

L-165041; L165041; L 165041; L-165,041; L165,041; L 165,041.

IUPAC/Chemical Name

2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]-acetic acid

InChi Key

HBBVCKCCQCQCTJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H26O7/c1-3-5-19-20(11-10-18(15(2)23)22(19)26)28-13-4-12-27-16-6-8-17(9-7-16)29-14-21(24)25/h6-11,26H,3-5,12-14H2,1-2H3,(H,24,25)

SMILES Code

O=C(O)COC1=CC=C(OCCCOC2=CC=C(C(C)=O)C(O)=C2CCC)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.

In vitro activity:

The PPARβ agonist L-165041 induces VEGF(121), VEGF(165) and VEGF(189) expression in HPV (Human Papillomavirus) positive HeLa cells but not in HPV negative cells. Reference: Cell Signal. 2014 Feb;26(2):433-43. https://pubmed.ncbi.nlm.nih.gov/24172859/

In vivo activity:

The overall hatching rate was higher in L-165041 (66.62±2.83% vs 53.19±2.90%). There was less lipid accumulation in fresh L-165041-embryos. In conclusion, the use of L-165041 is recommended to improve the viability of in vitro -derived bovine embryos. Reference: Reprod Fertil Dev. 2022 May;34(9):658-668. https://pubmed.ncbi.nlm.nih.gov/35468312/

	Solvent	mg/mL	mM
Solubility
	DMF	50.0	124.24
	DMF:PBS (pH 7.2) (1:1)	0.5	1.24
	DMSO	40.1	99.59

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 402.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Roche E, Lascombe I, Bittard H, Mougin C, Fauconnet S. The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism. Cell Signal. 2014 Feb;26(2):433-43. doi: 10.1016/j.cellsig.2013.10.006. Epub 2013 Oct 28. PMID: 24172859. 2. Park JH, Lee KS, Lim HJ, Kim H, Kwak HJ, Park HY. The PPARδ ligand L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ. J Cell Biochem. 2012 Jun;113(6):1947-54. doi: 10.1002/jcb.24063. PMID: 22234939. 3. Sánchez Viafara JA, de Vasconcelos GL, Maculan R, Alves NG, Ferreira MBD, Sudano MJ, Mingoti GZ, Nunes GB, de Lima RR, Drumond RM, Dos Santos RN, Eberlin MN, Negrão F; Jasmin; Donato MAM, Peixoto CA, Camisão de Souza J. Peroxisome proliferator-activated receptor delta-PPARδ agonist (L-165041) enhances bovine embryo survival and post vitrification viability. Reprod Fertil Dev. 2022 May;34(9):658-668. doi: 10.1071/RD21245. PMID: 35468312. 4. Lim HJ, Park JH, Lee S, Choi HE, Lee KS, Park HY. PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice. Eur J Pharmacol. 2009 Nov 10;622(1-3):45-51. doi: 10.1016/j.ejphar.2009.09.002. Epub 2009 Sep 18. PMID: 19766624.

In vitro protocol:

In vivo protocol:

1. Sánchez Viafara JA, de Vasconcelos GL, Maculan R, Alves NG, Ferreira MBD, Sudano MJ, Mingoti GZ, Nunes GB, de Lima RR, Drumond RM, Dos Santos RN, Eberlin MN, Negrão F; Jasmin; Donato MAM, Peixoto CA, Camisão de Souza J. Peroxisome proliferator-activated receptor delta-PPARδ agonist (L-165041) enhances bovine embryo survival and post vitrification viability. Reprod Fertil Dev. 2022 May;34(9):658-668. doi: 10.1071/RD21245. PMID: 35468312. 2. Lim HJ, Park JH, Lee S, Choi HE, Lee KS, Park HY. PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice. Eur J Pharmacol. 2009 Nov 10;622(1-3):45-51. doi: 10.1016/j.ejphar.2009.09.002. Epub 2009 Sep 18. PMID: 19766624.

1: Roche E, Lascombe I, Bittard H, Mougin C, Fauconnet S. The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism. Cell Signal. 2014 Feb;26(2):433-43. doi: 10.1016/j.cellsig.2013.10.006. Epub 2013 Oct 28. PubMed PMID: 24172859. 2: Park JH, Lee KS, Lim HJ, Kim H, Kwak HJ, Park HY. The PPARδ ligand L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ. J Cell Biochem. 2012 Jun;113(6):1947-54. doi: 10.1002/jcb.24063. PubMed PMID: 22234939. 3: Lim HJ, Park JH, Lee S, Choi HE, Lee KS, Park HY. PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice. Eur J Pharmacol. 2009 Nov 10;622(1-3):45-51. doi: 10.1016/j.ejphar.2009.09.002. Epub 2009 Sep 18. PubMed PMID: 19766624. 4: Lim HJ, Lee S, Park JH, Lee KS, Choi HE, Chung KS, Lee HH, Park HY. PPAR delta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis. 2009 Feb;202(2):446-54. doi: 10.1016/j.atherosclerosis.2008.05.023. Epub 2008 May 21. PubMed PMID: 18585719.